We foresee the necessity of further studies that examine the targeting both of tumor-intrinsic factors and proinflammatory and immunosuppressive TMEs to better cover the complexity of KRAS-mutant NSCLC and provide more personalized treatment based on the genetic assessment of each patient. The gene discussed is KRAS; the disease is neoplasm.